Table 2—

Mean percent difference of BMD in grams per centimeter squared between ALN and placebo groups among women with and without type 2 diabetes at 3 years, by site of BMD measurement

Diabetic women
Nondiabetic women
P value, test for homogeneity*
ALNPlaceboALNPlacebo
Lumbar spine
n1361372,8252,830
 Percent change from baseline6.6 ± 0.50.9 ± 0.47.5 ± 0.11.3 ± 0.1
 Percent difference (95% CI)5.7 (4.4–7.0)6.2 (5.9–6.4)0.4
Hip
n1371392,8422,847
 Total hip
  Percent change from baseline2.4 ± 0.4−1.9 ± 0.43.1 ± 0.1−1.2 ± 0.1
  Percent difference4.3 (3.2–5.3)4.3 (4.1–4.5)0.6
 Femoral neck
  Percent change from baseline2.6 ± 0.5−0.8 ± 0.6§3.4 ± 0.1−0.5 ± 0.1
  Percent difference3.4 (2.1–4.7)3.8 (3.6–4.1)0.6
 Trochanter
  Percent change from baseline4.1 ± 0.5−1.0 ± 0.4§4.9 ± 0.1−0.5 ± 0.1
  Percent difference5.1 (3.8–6.4)5.4 (5.1–5.7)1.0
 Intertrochanter
  Percent change from baseline1.8 ± 0.5−2.3 ± 0.42.4 ± 0.1−1.5 ± 0.1
  Percent difference4.0 (2.9–5.2)3.9 (3.7–4.1)0.4
  • Data are n, means ± SE, or means (95% CI).

  • *

    * P value for interaction between treatment and history of diabetes among all women combined;

  • P ≤ 0.001 vs. placebo;

  • P < 0.001 vs. baseline;

  • §

    § P ≤ 0.05 vs. baseline;

  • mean percent difference between alendronate and placebo groups.